Key Takeaways
- Strong quarter, broad-based growth: Revenue grew 22% YoY to ₹1,695.4 crore, with all segments contributing and Cenexi turning EBITDA-positive for the first time.
- Cenexi turnaround is now visible in the numbers: The acquired CDMO delivered EUR 50 million in revenue and EUR 1 million in EBITDA, validating the operational restructuring and integration thesis.
- GLP-1 story is building, but management is cautious on near-term ramp: Liraglutide launched in the US, semaglutide contracts signed, and cartridge capacity expanding from 4 crore to 14 crore units, yet the 3-4 year forecast deliberately underweights GLP-1 due to patent and pricing uncertainty.
- A ₹2,000 crore capex cycle is starting: Brownfield expansion over five years targets BFS, ophthalmics, lyophilizers and dedicated CDMO lines, with next year's spend above ₹400 crore and an expected asset turn above 3x.
- What to watch next quarter: Dalbavancin's US approval decision, the pace of new CDMO contract ramp-ups, and whether Cenexi sustains its positive EBITDA trajectory through calendar 2026.
Cenexi Turnaround & Integration
- Revenue recovery: Cenexi delivered EUR 50 million in Q3, up 21% in constant currency, with 9M revenue reaching EUR 138 million versus EUR 121 million last year.
- EBITDA inflection: The business generated EUR 1 million of positive EBITDA in Q3, in line with guidance, while the 9M EBITDA loss narrowed sharply to ₹38.3 crore from ₹128.3 crore a year ago.
- What drove the improvement: Capacity debottlenecking, contract re-pricing for inflation, workforce optimization, higher utilization and deeper operational integration with Gland all contributed.
- Synergies are becoming two-way: An integrated BD team now cross-sells capacities across both entities, joint tendering is underway with some volumes quoted from Cenexi and roughly 70% from Gland, and companies taking CDMO services from Cenexi are in discussions with Gland to in-license products.
- Capacity expansion underway: A new vial line under isolator is planned at Braine, a new combo line for prefilled syringes and cartridges arrives in 2026, an ampoule line is being expanded at Fontenay, and vial and combo lines are being added at BLA.
- The ask to investors: Management wants the Street to assess Cenexi and Gland as one integrated entity rather than two standalone stories, given the deepening operational and commercial linkages.
Srinivas Sadu: "So as a company, I think we should start looking at how Cenexi contributed to Gland, how Gland is contributed to Cenexi rather than independently looking at Cenexi."
US Business & Pricing Dynamics
- Volume-led growth: US revenue grew 16% YoY to ₹829 crore in Q3, with 9M reaching ₹2,344.6 crore; volume growth was almost 19% while price declined.
- GPO contracts driving the uptick: Contracts won three quarters ago for top-10 products began supplying from Q3/Q4 FY26, explaining the volume surge.
- Price erosion absorbed by efficiency: Prices dropped 5-6% but internal cost initiatives, including yield improvement, alternate vendor development and line efficiencies, allowed margins to be maintained and supported more aggressive pricing.
- Nine molecules launched: New launches in Q3 included Argatroban, Acetazolamide and Doxycycline; nine ANDAs were filed and four approvals received during the quarter.
- Milestone income shifted geographically: Milestone income from the US declined sharply, but the overall decrease was only 2% because most milestones now come from European contracts.
GLP-1, Peptides & Complex Injectables
- Liraglutide now commercial: The partner received US approval and Gland launched in January; the product was also launched in Canada last quarter.
- Semaglutide pipeline building: The company has signed contracts with several semaglutide generics players, positioning for future patent expiries.
- Cartridge capacity tripling: Fill-and-finish capacity is expanding from 4 crore to 14 crore units; the new line arrives next week, with validations taking four months and exhibit batches expected by Q2.
- Near-term forecast deliberately conservative: Management's 3-4 year outlook does not factor in significant GLP-1 contribution, citing patent uncertainty and unpredictable pricing evolution; the existing 4-crore line is expected to fill faster from insulin discussions.
- FY28 inflection expected: The pipeline includes 7-8 GLP-1 customers plus ongoing insulin discussions, and management stated FY28 will be "far, far better than FY27" for the cartridge line.
- Broader peptide and CDMO wins: New partnerships were secured across oncology, peptides and prefilled syringes, including long-term CDMO contracts for already-commercialized products requiring dedicated lines, with durable revenue visibility.
Srinivas Sadu: "So our next -- at least next 3-4 years forecast, we are not considering too much of GLP-1 because one is, of course, the patent situation and also the others [like] how the pricing will pan out."
Capex Cycle & Capacity Build-Out
- Five-year brownfield plan: Approximately ₹2,000 crore will be invested over five years, primarily toward BFS and ophthalmic lines as well as dedicated capacity for CDMO contracts; next year's capex will exceed ₹400 crore.
- Expected returns: Management targets an asset turn above 3x on the new facility and a hurdle rate of 20% IRR for any investment.
- Ophthalmic line: A new line with suspension capability is being added because current capacity is constrained and several products are under approval.
- BFS technology: Investment in Blow-Fill-Seal targets specialty products and the Rest of World business.
- Lyophilizer capacity: Existing lyo capacity will be exhausted within 1-1.5 years, necessitating further investment.
- Biologics CDMO: A greenfield facility is being built in Shamirpet adjacent to the existing 8 KL capacity; active discussions are underway with potential partners.
- New CDMO contract economics: One disclosed contract, with commercialization expected in late FY28, carries expected annual revenue of $25-30 million and requires approximately ₹80 crore in dedicated capex for a compounding area.
Margins, Mix & Cost Efficiency
- Gross margin trajectory: Q3 gross margin was 66%, broadly in line with the prior year and up from 63% in the previous quarter; 9M gross margins improved to 65% from 62%, driven by favorable business and product mix.
- Base business margins: Q3 base business gross margin was 61% versus 63% last year, reflecting product mix; 9M base margins improved to 60% from 57%.
- Base business EBITDA: Q3 adjusted EBITDA for the base business was ₹434.2 crore, representing a 37% margin.
- Cost savings as a structural lever: Ongoing initiatives, including yield improvement, alternate vendor development, alternative energy sourcing, enhanced line efficiencies and automation, typically deliver 1-2 percentage points of savings, helping offset pricing pressure or mix headwinds.
- R&D investment rising: R&D spend reached ₹65 crore or 5.4% of sales, up from ₹43.7 crore last year, focused on complex injectables, advanced delivery systems and platform-based development.
- Margin resilience despite price drops: Prices declined 5-6% in the US, but internal cost reduction allowed margins to be maintained, enabling more aggressive pricing where needed.
Srinivas Sadu: "So if you see there was a price drop of almost 5%-6%, if you compare to the period, we still were able to maintain the margins because our costs have come down."
Pipeline, Partnerships & Long-Term Bets
- RTU bags portfolio: 20 products filed, 16 approved, 13 under development.
- Core development pipeline: 15 products under active development, comprising seven 505(b)(2) filings and eight ANDAs.
- Dalbavancin: Approved and launched in six European countries in December; the US goal date was in February, with additional data submitted in January; European launches will partially offset any delay in the US.
- Co-development partnerships: 15 products are slated to begin in 2028; management declined to quantify the total addressable market when asked, deferring the question.
- Europe in-licensing: Four products were licensed in Europe last quarter.
- Inactivated vaccine and sterile gel: Both are ramping quarter by quarter and expected to continue growing.
- Strategic framing: Management is positioning Gland as a high-end, innovation-led CDMO and specialty injectables company, anchored on growth, capability, efficiency and return on capital employed.
Srinivas Sadu: "India's pharmacy industry is undergoing one of the most exciting transformations in global health care. Rising R&D investments are fuelling complex molecules, novel therapies and deeper manufacturing capabilities. This is not just growth - it's strategic evolution. India pharma is going from being the pharmacy of the world to becoming a global innovation hub."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Base business growth floor | Minimum 12-13% growth; higher if CMS approval in Europe accelerates | Ongoing / FY26+ |
| Long-term organic CAGR | 15% CAGR over 5 years, organic, excluding inorganic moves | 5-year horizon |
| Cenexi EBITDA | Remain positive on an annualized basis; quarter-to-quarter fluctuation expected | FY26 and beyond |
| Cenexi strategic returns | Investments to begin delivering meaningful results | Calendar 2026 onwards |
| Brownfield capex | Approximately ₹2,000 crore total; next year above ₹400 crore | Over next 5 years |
| Asset turn on new facility | More than around 3x | On commissioning |
| New CDMO contract commercialization | $25-30 million annual revenue; ₹80 crore dedicated capex | FY28 Q3/Q4 |
| Cartridge line readiness | New line delivered next week; validations 4 months; exhibit batches by Q2 | Q2 FY27 |
| Dalbavancin US approval | Goal date in February; additional data submitted in January | Decision awaited |
| CMS variation approval in Europe | Approval expected in 6 months | ~H2 CY26 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹1,695.4 crore, up 22% YoY |
| Base business revenue (ex-Cenexi) | ₹1,179 crore, up 16% YoY |
| Cenexi revenue | €50 million, up 21% YoY in constant currency; ₹516.4 crore, up 39% YoY |
| US revenue | ₹829 crore, up 16% YoY |
| Europe and other regulated markets revenue | ₹88.1 crore, up 16% YoY |
| Rest of World revenue | ₹187.6 crore, up 12% YoY |
| India revenue | ₹74.4 crore, up 32% YoY |
| Consolidated adjusted EBITDA | ₹449 crore, up 25% YoY; margin 26% |
| Base business adjusted EBITDA margin | 37% |
| Cenexi EBITDA | €1 million (₹14.8 crore), positive vs loss last year |
| Consolidated adjusted PAT | ₹279.7 crore, margin 16% vs 15% in Q3 FY25 |
| Overall gross margin | 66%, broadly in line with previous year, up from 63% in Q2 FY26 |
| Base business gross margin | 61% vs 63% last year, primarily due to product mix |
| R&D spend | ₹65 crore, 5.4% of revenue, up from ₹43.7 crore last year |
| US volume growth | ~19% YoY, while price dropped 5%-6% |
| Cash conversion cycle | 166 days for 9M FY26, improved from 172 days at end of FY25 |
| Total cash and equivalents | ₹3,052.5 crore as of Dec 31, 2025, including non-callable deposit of ₹396 crore |
| External debt (Cenexi level) | ₹336.3 crore |
| Capex incurred (9M FY26) | ₹356.6 crore |
| FY26 full-year capex guidance (base business) | ~₹250 crore |
| Cartridge fill and finish capacity | 4 crore units currently; expanding to 14 crore units |
| ANDA filings in the quarter | 9 filed, 4 approvals received, 9 products launched in the US |
| RTU bags portfolio | 20 filed, 16 approved, 13 under development; market opportunity of $685 million |
| Core development pipeline | 15 products under active development: 7 505(b)2 filings, 8 ANDAs |
| New CDMO contract expected annual revenue | $25 million to $30 million, starting end of FY28 |
| Organic growth outlook | 15% CAGR over 5 years |